BVS have been investigated for the treatment of FP disease with both PLLA-based and poly-lactide coglycolide-based scaffolds. The first of the studies was the PERSEUS study, which evaluated the non-drugeluting Igaki-Tamai PLLA stent (Kyoto Medical, Kyoto, Japan). This trial included 45 claudicants with lesions of <60 mm in length (11). Although the technical success rate for these noncomplex lesions was 100%, the 6-month restenosis rate was a disappointing 30%. In a separate study with similar lesion characteristics, the non-drug-eluting Igaki-Tamai BVS
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